Providing Solutions to The Most Pressing Challenges in the Ophthalmic Gene Therapy Space

View the Full Event Guide
Access the latest agenda, speaker line-up, networking opportunities and more

Partner With Us
Partner with the Gene Therapy for Ophthalmic Disorders summit 2022 to share your solutions with leaders in the field

Revolutionizing Genetic Therapy Development & Delivery to the Eye

The Race Is On; Luxturna Remains the Only Approved Gene Therapy for the Eye, Who Will Be the Next?

The 3rd Annual Gene Therapy for Ophthalmic Disorders meeting is bringing you even more world class content, bringing you two tracks of learning to tackle the pressing challenges faced in the pre-clinical stages and in clinical development. This includes challenges faces with drug targets including wet AMD, dry AMD, DME, IRDs and more.

Join 40+ speakers from the industry leaders in ophthalmic gene therapy such as: Adverum, REGENXBIO, Novartis, Janssen, Kriya, Nanoscope, IVERIC, GenSight, SparingVision, Atsena, AGTC, ViGeneron and many more as we discover novel vector engineering, disease models, clinical trials design, patient enrolment platforms and more.

This year an additional day to compliment the scientific program has been added. The NEW hotly anticipated post-conference delivery day will address the devices and technology involved in the delivery of these drugs. Additionally, our beloved pre-conference workshop day now has four thought-provoking workshops, covering topics that lend better to longer, more interactive discussions such as: non-viral modalities & US & EU regulatory considerations.

Join 150+ stake holders within the industry to overcome these challenges and get these drugs to the ophthalmic gene therapy patients who needs them as fast as possible. Download full event guide here.

World-Class Speaker Faculty

Abraham Scaria

Chief Scientific Offier

IVERIC Bio

Ashwath Jayagopal

Chief Scientific Officer

Opus Genetics

Catherine O’Riordan

Head Translational Cluster, Genomics Unit

Sanofi

Daniel Chung

Chief Medical Officer

SparingVision

Hemant Khanna

Vice President of Preclinical Ocular Research

IVERIC Bio

Linda Couto

Chief Scientific Officer

Atsena

Richard Beckman

Chief Medical Officer

Adverum

Stylianos Michalakis

Co-founder & Chief Scientific Advisor

ViGeneron

Theresa Heah

President & Chief Medical Officer

Kriya Ophthalmology

William Beltran

Director, Division of Experimental Retinal Therapies

University of Pennsylvania

Proud to Partner With

Forge Biologics Primary Logo Square
Biomere logo
8iGViy2y (002)

2021 Attendee Snapshot

Gene Therapy for Ophthalmic Disorders 2021

Other Events in the Gene Therapy Series